The approved product has an estimated market size of US$ 44.5 million for the twelve months ending January 2024
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Neurontin Tablets, 600 mg and 800 mg, of Viatris Specialty
The product will be launched in March 2024
The Pregabalin capsules has a market size of ~US$248 mn per IQVIA
The product is expected to be launched in December 2023
Pantoprazole Sodium Delayed-Release Tablets are indicated for short-term treatment of Erosive Esophagitis associated with GERD
The current annual U.S. market for Sildenafil for Oral Suspension is approximately $43 million
The product is expected to be launched in FY25
The Product will be manufactured at the company's facility in Bengaluru
Subscribe To Our Newsletter & Stay Updated
